000			01542 a2200397 4500
005			20250517102743.0
264		0	_c20170213
008			201702s 0 0 eng d
022			_a1769-6658
024	7		_a10.1016/j.canrad.2016.03.010 _2doi
040			_aNLM _beng _cNLM
100	1		_aGéraud, A
245	0	0	_aPreliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. _h[electronic resource]
260			_bCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _cJun 2016
300			_a312-3 p. _bdigital
500			_aPublication Type: Letter
650	0	4	_aAdo-Trastuzumab Emtansine
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBone Neoplasms _xsecondary
650	0	4	_aBreast Neoplasms _xmetabolism
650	0	4	_aChemoradiotherapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMaytansine _xanalogs & derivatives
650	0	4	_aMiddle Aged
650	0	4	_aRadiation Dose Hypofractionation
650	0	4	_aReceptor, ErbB-2 _xmetabolism
650	0	4	_aTrastuzumab
700	1		_aXu, H P
700	1		_aBeuzeboc, P
700	1		_aKirova, Y M
773	0		_tCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _gvol. 20 _gno. 4 _gp. 312-3
856	4	0	_uhttps://doi.org/10.1016/j.canrad.2016.03.010 _zAvailable from publisher's website
999			_c26159860 _d26159860